Trial reportBJU international2016
A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
Trial report in BJU international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline.BMJ (Clinical research ed.) · 2018Guideline
- Patients with high-risk features on active surveillance for prostate cancer.Prostate international · 2026Review
- Monoclonal Gammopathy Prevalence in Newly Diagnosed Prostate Cancer Patients: A Correlative Perspective Observational Study.Cancers · 2025Article
- Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial.International journal of cancer · 2025Article
- Cross-tissue transcriptome-wide association studies identify genetic susceptibility genes for prostate cancer.BMC cancer · 2025Article
- Human papillomavirus infection among men and its role in the etiology of prostate cancer: A prospective study.Central European journal of urology · 2025Article
- A retrospective study of prostate-specific antigen and international prostate symptoms scores from participants at a men's health screening initiative in Trinidad.Journal of family medicine and primary care · 2024Article
- Variation in harms and benefits of prostate-specific antigen screening for prostate cancer by socio-clinical risk factors: A rapid review.BJUI compass · 2024Review
- The Risk Factors and Screening Uptake for Prostate Cancer: A Scoping Review.Healthcare (Basel, Switzerland) · 2023Article
- Association between obesity and frequency of high-grade prostate cancer on biopsy in men: A single-center retrospective study.Molecular and clinical oncology · 2022Article
- Association of Family History of Cancer with Clinical and Pathological Outcomes for Prostate Cancer Patients on Active Surveillance.The Journal of urology · 2022Article
- Genetic predisposition to prostate cancer: an update.Familial cancer · 2022Review
- [Familial prostate cancer and genetic predisposition].Der Urologe. Ausg. A · 2021Review
- Family history of prostate cancer and prostate tumor aggressiveness in black and non-black men;results from an equal access biopsy study.Cancer causes & control : CCC · 2021Article
- Peri-prostatic adipose tissue measurements using MRI predict prostate cancer aggressiveness in men undergoing radical prostatectomy.Journal of endocrinological investigation · 2021Article
- Rethinking prostate cancer screening: could MRI be an alternative screening test?Nature reviews. Urology · 2020Review
- Polyphenol Extracts from Red Wine and Grapevine: Potential Effects on Cancers.Diseases (Basel, Switzerland) · 2018Review
- Prostate cancer screening: what can we learn from randomised trials?Translational andrology and urology · 2018Review
- Prostate cancer screening-when to start and how to screen?Translational andrology and urology · 2018Review
- The impact of moderate wine consumption on the risk of developing prostate cancer.Clinical epidemiology · 2018Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 4 countries.
Funding
Abstract
objectiveTo assess the value of a positive family history (FH) as a risk factor for prostate cancer incidence and grade among men undergoing organised prostate-specific antigen (PSA) screening in a population-based study. SUBJECTS AND
methodsThe study cohort comprised all attendees of the Swiss arm of the European Randomised Study of Screening for Prostate Cancer (ERSPC) with systematic PSA level tests every 4 years. Men reporting first-degree relative(s) diagnosed with prostate cancer were considered to have a positive FH. Biopsy was exclusively PSA triggered at a PSA level threshold of 3 ng/mL. The primary endpoint was prostate cancer diagnosis. Kaplan-Meier and Cox regression analyses were used.
resultsOf 4 932 attendees with a median (interquartile range, IQR) age of 60.9 (57.6-65.1) years, 334 (6.8%) reported a positive FH. The median (IQR) follow-up duration was 11.6 (10.3-13.3) years. Cumulative prostate cancer incidence was 60/334 (18%, positive FH) and 550/4 598 (12%, negative FH) [odds ratio 1.6, 95% confidence interval (CI) 1.2-2.2, P = 0.001). In both groups, most prostate cancer diagnosed was low grade. There were no significant differences in PSA level at diagnosis, biopsy Gleason score or Gleason score on pathological specimen among men who underwent radical prostatectomy between both groups. On multivariable analysis, age (hazard ratio [HR] 1.04, 95% CI 1.02-1.06), baseline PSA level (HR 1.13, 95% CI 1.12-1.14), and FH (HR 1.6, 95% CI 1.24-2.14) were independent predictors for overall prostate cancer incidence (all P < 0.001). Only baseline PSA level (HR 1.14, 95% CI 1.12-1.16, P < 0.001) was an independent predictor of Gleason score ≥7 prostate cancer on prostate biopsy. The proportion of interval prostate cancer diagnosed in-between the screening rounds was not significantly different.
conclusionIrrespective of the FH status, the current PSA-based screening setting detects the majority of aggressive prostate cancers and missed only a minority of interval cancers with a 4-year screening algorithm. Our results suggest that men with a positive FH are at increased risk of low-grade but not aggressive prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.